Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.

This review summarizes literature and experiences on the skin manifestations in COVID-19 patients, suggesting some may help identify asymptomatic cases, but it reports no new clinical results.

This study found that the prevalence of dermatological manifestations in COVID-19 patients was 1.7% in Sri Lanka, with various types of skin lesions reported.

COVID-19 can cause different skin issues, including rashes and hair loss.

This review examined dermatologic symptoms associated with COVID-19 in 2,560 patients, with chilblains/pernio-like lesions being the most common, suggesting these symptoms may aid in early identification of cases.

This review focuses on the various skin symptoms associated with COVID-19 but reports no new clinical findings.

This study found that patients with Stevens-Johnson syndrome and toxic epidermal necrolysis exhibit lower levels and activity of DNase1, impairing NET degradation, and suggests DNase1 administration as a potential treatment.

This correspondence presents no new clinical findings about COVID-19 dermatological manifestations but references the Mexican Academy of Dermatology's COVID-19 registry.

In this case report, the authors suggest that methotrexate-induced rheumatoid papular eruption is a rare side effect of methotrexate, resolved after discontinuation, which may be linked to rheumatic conditions.

This review discusses mucocutaneous manifestations associated with Covid-19, classifies the lesions, and describes their characteristics and treatments but reports no new clinical findings.

This case report identified a maculopapular rash in a 76-year-old male, occurring 2 months after starting Finasteride for prostatic hyperplasia, with clinical and histologic evidence suggesting a drug-induced skin eruption.

COVID-19 can cause or worsen skin conditions and might show early signs of infection.

This review discusses the cutaneous symptoms associated with COVID-19 and their potential use in diagnosing and assessing the severity of the disease, but it reports no new clinical results.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This review discusses dermatologic manifestations of COVID-19, highlighting the possibility that skin signs might be the initial indicators of infection, though it reports no new clinical results.

This review details various skin manifestations linked to COVID-19 and highlights dermatitides caused by personal protective equipment, emphasizing the need for accurate diagnosis and prompt treatment.

This study documented a variety of skin lesions in COVID-19 patients, indicating that skin rashes might be an early or sole symptom of the disease.

This study found no increased frequency of the TNF2 allele in Mexican patients with adverse cutaneous drug reactions mediated by delayed hypersensitivity, suggesting its lower relevance compared to findings in Caucasian populations.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

In this cross-sectional study of COVID-19 positive patients in Bangladesh, researchers found that maculo-papular eruptions were the most common dermatological manifestation, with other prevalent conditions including chilblain-like eruptions, urticarial lesions, and petechiae/purpura.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This study suggests that minoxidil may improve hypotrichosis in patients with ARWH due to LIPH variants, but a possible genetic factor could affect its efficacy within families.

This review discusses various skin infections and conditions that commonly occur in patients with HIV, but it does not report new research findings.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

This review discusses the distinctive non-infective skin presentations of HIV infection from a dermatological perspective and reports no new clinical findings.

This study conducted at Madras Veterinary College found that tick infestation was the most frequent diagnosis among hospitalized dogs with dermatological issues, with ectoparasiticides prescribed in 73% of cases.

This review discusses the diagnosis and management of severe cutaneous adverse reactions to drugs and provides guidance for physicians to improve patient outcomes, but it reports no new clinical results.

This case study highlights that even short-term use of hydroxychloroquine for COVID-19 can potentially lead to acute generalized exanthematous pustulosis as an adverse effect.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.